If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Rallybio Corporation (RLYB)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Their mission at Rallybio is aligned with their expertise, and they believe they have assembled the best people, partners and science to forge new paths to life-changing therapies. Since their launch in January 2018, they have acquired a portfolio of promising product candidates that consists of five programs, and they are focused on further expanding their portfolio with the goal of making a profound impact on the lives of even more patients. They are drawing on their decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible – and change the odds for rare disease patients. Their most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. They are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial, which they believe has established proof of concept for RLYB211 and provides support for their proposed mechanism of action. They plan to move their FNAIT program forward with their lead product candidate, RLYB212, a monoclonal anti-HPA-1a antibody.
Pharmaceutical Preparations
Martin W. Mackay Jeffrey M. Fryer
Employees Founded
28 2018


Address: 234 Church Street, Suite 1020 New Haven, Ct 06510

Telephone: (203) 859-3820

Web page:

IPO information

First Trade Date 7/29/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5.75
Shares Revised (MM) 6.2
Expected offer amount (MM) $80.5
Realized offer amount(MM) $80.6

Financial Data (last reporting year)

Market Cap (MM) $430.5
Revenues (MM) $0
Net Income (Loss) (MM) $-35.85


What do you think will happen with the RLYB share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Jefferies

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Jefferies/ Cowen/ Evercore ISI

Sector: Healthcare

Tweets about $RLYB

Tweets volume:

RT volume:


Google Trends Stats